Cellular and molecular gateways to urolithiasis: A new insight

Urologia Internationalis

Volumn 74, Issue 3, 2005, Pages 193-197

  Dal Moro, Fabrizio ^a   Mancini, Mariangela ^a   Tavolini, Ivan Matteo ^a   De Marco, Vincenzo ^a   Bassi, Pierfrancesco ^a,b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; BIOMINERALIZATION; CELL DAMAGE; EQUILIBRIUM CONSTANT; GENETIC ANALYSIS; HEALTH CARE SYSTEM; HUMAN; MOLECULAR DYNAMICS; PRIORITY JOURNAL; REVIEW; UROLITHIASIS; ACTIVE TRANSPORT; ANIMAL; CRYSTALLIZATION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CALCIUM; CYSTEINE; MAGNESIUM DERIVATIVE; PHOSPHATE; STRUVITE; URIC ACID;

ANIMALS; APOPTOSIS; BIOLOGICAL TRANSPORT, ACTIVE; CALCIUM; CRYSTALLIZATION; CYSTEINE; HUMANS; MAGNESIUM COMPOUNDS; PHOSPHATES; URIC ACID; URINARY CALCULI;

EID: 21244443365     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083547     Document Type: Review

References (42)

1. Serio A, Fraioli A: Epidemiology of nephrolithiasis. Nephron Suppl 1999;81:26-30.
2. Rivers K, Shetty S, Menon M: When and how to evaluate a patient with nephrolithiasis. Urol Clin North Am 2000;27:203-213.
3. Prien EL, Prien EL Jr: Composition and structure of urinary stone. Am J Med 1968;45:654-672.
4. Elliot JS: Structure and composition of urinary calculi. J Urol 1973;109:82-83.
5. Boyce WH: Organic matrix of human urinary concentrations. Am J Med 1968;95:673-683.
6. Dussol B, Geider S, Lilova A, et al: Analysis of the soluble organic matrix of five morphologically different kidney stones - Evidence for a specific role of albumin in the constitution of stone matrix protein. Urol Res 1994;23:45-51.
7. Rodman J, Seidman C, Jones R: No More Kidney Stones. New York, Wiley, 1996, p 5.
8. Jones G, Hogan DB, Yent DB, et al: Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. Vitamin D metabolites and analogs in the treatment of osteoporosis. Can Med Assoc J 1996;155:955-961.
9. Seftel A, Resnick MI: Metabolic evaluation of urolithiasis. Urol Clin North Am 1990;17:159-169.
10. Wu X, Wakamiya M, Vaishnav S, et al: Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci USA 1994;91:742-746.
11. Hedelin H, Grenabo L, Pettersson S: Urease-induced crystallization in synthetic urine. J Urol 1985;133:529-533.
12. McLean RJC, Nickel JC, Cheng KJ, et al: The ecology and pathogenicity of urease-producing bacteria in the urinary tract. Crit Rev Microbiol 1988;16:37-79.
13. Dello Strologo L, Pras E, Pontesilli C, et al: Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: A need for a new classification. J Am Soc Nephrol 2002;13:2547-2553.
14. Hallson PC, Rose GA: Crystalluria in normal subjects and in stone formers with and without thiazide and cellulose phosphate treatment. Br J Urol 1976;48:515-524.
15. Werness PG, Wilson JWL, Smith LH: Hydroxyapatite and its role in calcium urolithiasis; in Ryall RL, Brockis JG, Marshall VR, Finlayson B (eds): Urinary Stones. London, Churchill Livingstone, 1984, pp 273-277.
16. Daudon M, Hennequin C, Bader C, et al: Inhibitors of crystallization. Adv Nephrol 1995;24:167-169.
17. Nicar M, Skurla C, Sakhaee K, et al: Low urinary citrate excretion in nephrolithiasis. Urology 1983;21:8-11.
18. Whalley NA, Meyers AM, Martins M, et al: Long-term effects of potassium citrate therapy on the formation of new stones in groups of recurrent stone formers with hypocitraturia. Br J Urol 1996;78:10-13.
19. Ryall RL, Grover PK, Harnett RM, et al: Small molecular weight inhibitors; in Walker VR, Sutton RAL, Cameron ECB, Pak CYC, Robertson WG (eds): Urolithiasis. New York, Plenum, 1989, pp 91-96.
20. Hodgkinson A: Citric acid excretion in normal adults and in patients with renal calculus. Clin Sci 1962;23:203-212.
21. Elliot JS, Ribiero ME: The urinary excretion of citrate, hippuric acid and lactic acid in normal adults and in patients with calcium oxalate urinary calculus disease. Invest Urol 1972;10:102-106.
22. Schwille PO, Scholz D, Schwille K, et al: Citrate in urine and serum and associated variables in subgroups of urolithiasis. Nephron 1982;31:194-202.
23. Cicerello E, Merlo F, Gambaro G, et al: Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. J Urol 1994;151:5-9.
24. Doremus RH, Teich S, Silvis PX: Crystallization of calcium oxalate from synthetic urine. Invest Urol 1978;15:469-472.
25. Lieske JC, Toback FG: Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol 1993;264:800-804.
26. Tsujihata M, Miyake O, Yoshimura K, et al: Fibronectin as a potent inhibitor of calcium oxalate urolithiasis. J Urol 2000;164:1718-1723.
27. Goodmann HO, Holmes RP, Assimos DG: Genetic factors in calcium oxalate stone disease. J Urol 1995;153:301-307.
28. Resnick M, Pridgen DB, Goodman HO: Genetic predisposition to formation of calcium oxalate renal calculi. N Engl J Med 1968;278:1313-1318.
29. Khan SR: Pathogenesis of oxalate urolithiasis: Lessons form experimental studies with rats. Am J Kidney Dis 1991;17:398-401.
30. Khan SR, Thamiselvan S: Nephrolithiasis, consequences of renal epithelial cell exposure to oxalate and calcium oxalate crystals. Mol Urol 2000;4:305-312.
31. Chaturvedi LS, Koul S, Bhandari A, et al: Oxalate selectively activates p38 mitogen-activated protein kinase and c-Jun N-terminal kinase signal transduction pathways in renal epithelial cells. J Biol Chem 2002;277:13321-13330.
32. Lahme S, Dyballa S, Feil G, et al: Effect of selenium on renal tubular alteration. Eur Urol 2002;1(suppl):81.
33. Thamiselvan S, Khan SR, Menon M: Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: Effect of anti-oxidant. Urol Res 2003;31:3-9.
34. Hsieh N, Shih CH, Chen HY, et al: Effects of Tamm-Horsfall protein on the protection of MCDK cells from oxalate induced free radical injury. Urol Res 2003;31:10-16.
35. Khan SR, Hackett RL: Calcium oxalate urolithiasis in the rat: Is it a model for human stone disease? A review of recent literature. Scan Electron Microsc 1985;2:759-774.
36. Khan SR: Animal models of kidney stone formation: An analysis. World J Urol 1997;15:236-243.
37. Khan SR, Glenton PA, Backov R, et al: Presence of lipids in urine, crystals and stone: Implications for the formation of kidney stones. Kidney Int 2002;62:2062-2072.
38. Khan SR, Shevock PN, Hackett RL: In vitro precipitation of calcium oxalate in the presence of whole matrix or lipid components of the urinary stones. J Urol 1988;139:418-422.
39. Boskey AL: Role of calcium-phospholipid-phosphate complexes in tissue mineralization. Metab Bone Dis Relat Res 1978;1:137-142.
40. Janassen JA, Cao LC, Honeyman T, et al: Mechanisms mediating oxalate-induced alterations in renal function. Crit Rev Eukaryot Gene Expr 2003;13:55-72.
41. Wencker D, Chandra M, Nguyen K, et al: A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003;111:1497-1504.
42. Ljunghall S: Incidence of upper urinary tract stones. Miner Electrolyte Metab 1987;13:220-227.